WO2020143781A1 - Forme cristalline d'un composé hétérocyclique servant d'antagoniste du récepteur crth2 - Google Patents

Forme cristalline d'un composé hétérocyclique servant d'antagoniste du récepteur crth2 Download PDF

Info

Publication number
WO2020143781A1
WO2020143781A1 PCT/CN2020/071479 CN2020071479W WO2020143781A1 WO 2020143781 A1 WO2020143781 A1 WO 2020143781A1 CN 2020071479 W CN2020071479 W CN 2020071479W WO 2020143781 A1 WO2020143781 A1 WO 2020143781A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
formula
crystal form
heterocyclic compound
hydrate
Prior art date
Application number
PCT/CN2020/071479
Other languages
English (en)
Chinese (zh)
Inventor
吕硕
孙晓伟
孙若思
张红芬
杜丹
姚润润
刘翠艳
Original Assignee
石药集团中奇制药技术（石家庄）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 石药集团中奇制药技术（石家庄）有限公司 filed Critical 石药集团中奇制药技术（石家庄）有限公司
Priority to CN202080007335.XA priority Critical patent/CN113382995A/zh
Publication of WO2020143781A1 publication Critical patent/WO2020143781A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Definitions

  • the present invention belongs to the technical field of pharmaceutical crystal forms, and specifically relates to the crystal forms of heterocyclic compounds as CRTH2 receptor antagonists.
  • Prostaglandin D2 (PGD 2 ) is a cyclooxygenase metabolite of arachidonic acid. It is released from mast cells and TH2 cells in response to immune challenge, and it has been suggested to play a role in different physiological events such as sleep and allergic reactions.
  • Receptors for PGD 2 include "DP" receptors, chemoattractant receptor homologous molecules ("CRTH2") expressed on TH2 cells, and "FP" receptors. These receptors are G protein coupled receptors activated by PGD 2 . CRTH2 receptor and its expression on different cells including human T helper cells, basophils and eosinophils have been expressed in Abe, etal., Gene227: 71-77, 1999, Nagata, etal., FEBSLetters459: 195-199, 1999 and Nagata, etal., The Journal of Immunology 162: 1278-1286, 1999, which describe CRTH2 receptors. Hirai, etal., J. Exp. Med. 193:255-261, 2001 proved that CRTH2 is a receptor for PGD 2 .
  • Th2-polarization has been found in allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis (Romagnani S. Immunology Today, 18, 263-266, 1997; Hammad H. et al., Blood , 98, 1135-1141, 2001).
  • Th2 cells regulate allergic diseases by producing Th2 cytokines, such as IL-4, IL-5, and IL-13 (Orissetal., J. Immunol., 162, 1999-2007, 1999; Violaetal., Blood, 91, 2223 -2230, 1998; Webbetal., J. Immunol., 165, 108-113, 2000; Dumont F. J., Exp. Opin. Ther.
  • Th2 cytokines directly or indirectly induce the migration, activation, priming and prolongation of effector cells such as eosinophils and basophils in allergic diseases (Sanzetal., J. Immunol., 160, 5637 -5645, 1998; Popeetal., J. AllergyClin. Immunol., 108, 594-601, 2001; Teran L.M., Clin. Exp. Allergy, 29, 287-290, 1999).
  • antagonists that inhibit the binding of CRTH2 to PGD 2 should be useful in the treatment of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis.
  • Chinese invention patent application CN101896178B discloses a heterocyclic compound represented by the following formula I as a CRTH2 receptor antagonist.
  • Example 3 discloses compounds of the following structure:
  • the present invention provides the following technical solutions:
  • the crystal form uses Cu-K ⁇ radiation, and the X-ray powder diffraction expressed at an angle of 2 ⁇ is 8.6 ⁇ 0.2°, 11.1 ⁇ 0.2°, 11.4 ⁇ 0.2°, 14.1 ⁇ 0.2°, 16.1 ⁇ 0.2°, 17.9 ⁇ There are characteristic peaks at 0.2°, 20.9 ⁇ 0.2°, 22.6 ⁇ 0.2°, 24.4 ⁇ 0.2°, and 25.8 ⁇ 0.2°.
  • the crystalline form uses Cu-K ⁇ radiation, and the X-ray powder diffraction expressed at a 2 ⁇ angle is 8.6 ⁇ 0.2°, 11.1 ⁇ 0.2°, 11.4 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.6 ⁇ 0.2°, 16.1 There are characteristic peaks at ⁇ 0.2°, 17.9 ⁇ 0.2°, 18.3 ⁇ 0.2°, 20.9 ⁇ 0.2°, 22.6 ⁇ 0.2°, 24.4 ⁇ 0.2°, 25.8 ⁇ 0.2°, 26.5 ⁇ 0.2°, 28.9 ⁇ 0.2°.
  • the crystal form has an X-ray powder diffraction pattern substantially as shown in FIG. 1.
  • the crystal form has a DSC-TGA spectrum substantially as shown in FIG. 2.
  • the crystal form of the heterocyclic compound represented by formula A is a hydrate, preferably a monohydrate. More preferably, the mass fraction of water in the hydrate is 4.2-5.2%, more preferably 4.5-5.0%.
  • the monohydrate is as follows:
  • the crystal form is a single crystal, having the following single crystal parameters:
  • the invention also provides a method for preparing the crystalline form of the heterocyclic compound represented by formula A or its hydrate, which includes the following steps:
  • the compound represented by formula A is placed in a mixed solvent composed of a ketone solvent and water, heated and dissolved, and then cooled, and crystallized by stirring to obtain the crystal form of the heterocyclic compound represented by formula A or its hydrate
  • the racemic body of the heterocyclic compound represented by Formula A is eluted on a Chiralcel OJ-RH column (Chiralcel Technologies) with a methanol solution containing 0.05% trifluoroacetic acid, and the heterocyclic compound represented by Formula A is isolated.
  • the ketone solvent is selected from acetone or methyl ethyl ketone.
  • the volume ratio of the ketone solvent to water is (1-3):1, for example, 1:1.
  • the heating temperature is 30 to 80°C, preferably 40 to 60°C.
  • the ability of the crystalline form of the heterocyclic compound represented by Formula A or its hydrate provided by the present invention to interact with prostaglandin receptors makes it possible to prevent or reverse the adverse symptoms caused by prostaglandins in mammals, especially human .
  • Such mimicry or antagonism of the action of prostaglandins indicates that the compounds of the present invention and their pharmaceutical compositions can be used to treat, prevent or improve respiratory conditions, allergic conditions, pain, inflammatory conditions in mammals, especially humans , Mucus secretion disease (mucussecretiondisorder), bone disease, sleep disease (sleepdisorder), fertility disease, blood coagulation disease (blood coagulationdisorder), vision problems and immune and autoimmune diseases.
  • this compound can also inhibit cell tumorigenic transformation and metastatic tumor growth, and thus can be used to treat various forms of cancer.
  • the crystalline form of the heterocyclic compound represented by formula A or its hydrate can also be used to treat and/or prevent prostaglandin-mediated proliferative diseases, such as proliferative diseases that may occur in diabetic retinopathy and tumor angiogenesis.
  • the crystalline form of the heterocyclic compound represented by Formula A or its hydrate can also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or simulated relaxing prostaglandins, and thus can It is used to treat dysmenorrhea, premature delivery and eosinophil-related diseases. More specifically, the crystalline form of the heterocyclic compound represented by Formula A or its hydrate is an antagonist of prostaglandin D2 receptor (CRTH2).
  • CRTH2 prostaglandin D2 receptor
  • the present invention also provides a method of antagonizing the PGD 2 receptor, including the CRTH2 receptor, which method comprises administering to a mammal in need thereof an effective amount of the crystalline form of the heterocyclic compound represented by Formula A or its hydrate.
  • Another aspect of the present invention provides a method of treating or preventing a prostaglandin-mediated disease, the method comprising administering to a mammalian patient in need of such treatment an amount that can effectively treat or prevent the prostaglandin-mediated disease A shows the crystalline form of the heterocyclic compound or its hydrate.
  • the crystal forms and compositions of the present invention can be used to treat prostaglandin-mediated diseases, including but not limited to allergic rhinitis, nasal congestion, runny nose, perennial rhinitis, rhinitis, asthma including allergic asthma, chronic obstructive pulmonary disease And other forms of pneumonia; sleep sickness and sleep-wake cycle disorder; dysmenorrhea and preterm labor associated with prostaglandin-induced smooth muscle contraction; eosinophil-related diseases; thrombosis; glaucoma and vision disorders; Occlusive vascular disease; congestive heart failure; diseases or conditions that require anticoagulant therapy, such as post-injury or post-operative treatment; inflammation; gangrene; Raynaud's disease; mucin secretion disorders including cell protection; pain and migraine; need Diseases that control bone formation and resorption, such as osteoporosis; shock; thermal regulation, including fever; and immune diseases or disorders that require immune regulation. More specifically, the diseases to be treated are diseases mediated by prostag
  • the present invention also provides a method of treating or preventing a prostaglandin-mediated disease, the method comprising administering to a mammalian patient in need of such treatment an amount of a heterocyclic compound represented by formula A that can effectively treat or prevent a prostaglandin-mediated disease Crystalline form, wherein the prostaglandin-mediated diseases are stuffy nose, rhinitis including allergic rhinitis and perennial rhinitis, and asthma including allergic asthma.
  • the present invention also provides a method of treating or preventing a prostaglandin D2-mediated disease, the method comprising administering to a mammalian patient in need of such treatment an heterocyclic ring of formula A in an amount effective to treat or prevent a prostaglandin D2-mediated disease
  • the crystalline form of the compound or its hydrate, wherein the disease mediated by prostaglandin D2 is nasal congestion or asthma.
  • the present invention also provides a method of treating nasal congestion in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of the heterocyclic compound represented by Formula A or a hydrate thereof.
  • the present invention also provides a method of treating asthma, especially allergic asthma, in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of the heterocyclic compound represented by Formula A or a hydrate thereof.
  • the administration of the compounds disclosed herein can be mixed with pharmaceutically acceptable excipients well known in the art. Specifically, as a drug for systemic administration, it can be formulated into capsules, powders, pills, tablets, etc. suitable for oral or parenteral administration or inhalation.
  • the crystalline form of the heterocyclic compound represented by formula A or its hydrate can be co-administered with other therapeutic agents. Therefore, another aspect of the present invention provides a pharmaceutical composition for treating prostaglandin-mediated diseases, which includes a therapeutically effective amount of the crystalline form of the heterocyclic compound represented by formula A or its hydrate and one or more Kinds of other therapeutic agents.
  • Suitable therapeutic agents used in combination therapy with the crystalline form of the heterocyclic compound represented by Formula A or its hydrate include: (1) DP receptor antagonists, such as S-5751 or laropiprant; 2) Corticosteroids, such as triamcinolone (acetonide); (3) ⁇ -agonists, such as salmeterol, formoterol, terbutaline, isoprotonin (metaproterenol) and albuterol (albuterol), etc.; (4) Leukotriene modifiers, including leukotriene receptor antagonists or lipooxygenase inhibitors, such as montelukast, montelukast Zafirlukast, pranlukast or zileuton; (5) antihistamines, such as bromopheniramine, chlorpheniramine, dexchlorobenzene Dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelen
  • the present invention provides the crystal form of the compound of formula A or its hydrate.
  • the inventor unexpectedly discovered that the crystalline form of the compound of formula A or its hydrate is superior to its amorphous form in terms of moisture absorption and stability. Moreover, the crystalline form also has better bioavailability than the amorphous form.
  • the preparation method of the compound of formula A or its hydrate is simple, can be applied in industry, and has higher practicability.
  • FIG. 1 is an XRPD spectrum of the crystal form obtained in Example 1.
  • FIG. 1 is an XRPD spectrum of the crystal form obtained in Example 1.
  • FIG. 2 is a DSC-TGA spectrum of the crystal form obtained in Example 1.
  • FIG. 3 is a three-dimensional structure diagram and cell diagram of the crystal form obtained in Example 1.
  • DSC-TGA test project instrument name and model synchronous thermal analyzer (STA449F3) 20 °C to 350 °C
  • the racemic compound (0.500 g) of the heterocyclic compound of formula A was eluted on a Chiralcel OJ-RH column (Chiralcel Technologies) with methanol containing 0.05% TFA and collected The eluate was concentrated to dryness to obtain about 0.2 g of product, which was amorphous. Add acetone (2.5mL) and water (2.5mL) to the concentrate, heat and dissolve at 40-50°C, then drop to 0-10°C, stir and crystallize for 2 to 3h, and filter to obtain the crystalline form of the heterocyclic compound of formula A ( 0.156g), the yield was 31.2%.
  • the XRPD detection results of the crystal form are shown in FIG. 1, and the DSC-TGA detection results are shown in FIG. 2. From the DSC chart of FIG. 2, it can be seen that the endothermic peaks appear at 86.4°C and 130.4°C, respectively, and the TGA loses weight. The graph shows a weight loss of 4.29%.
  • the DSC-TGA pattern of the crystal form indicates that the crystal form is a monohydrate.
  • 3 is a three-dimensional structure diagram and unit cell diagram of the obtained crystal form.
  • pH1.0 medium take 9.0mL of hydrochloric acid, dilute with water to 1000mL, shake well, then you get.
  • pH4.5 medium take 6.80g of potassium dihydrogen phosphate (KH 2 PO 4 ), add appropriate amount of water to dissolve and dilute to 1000mL, adjust the pH value to 4.5 with phosphoric acid or sodium hydroxide, shake well, then you get.
  • KH 2 PO 4 potassium dihydrogen phosphate
  • pH6.8 medium take 55.38g of disodium hydrogen phosphate (Na 2 HPO 4 ⁇ 12H 2 O) and 4.77g of citric acid (C 6 H 8 O 7 ⁇ H 2 O), add appropriate amount of water to dissolve and dilute to 1000mL, Adjust the pH to 6.8 with phosphoric acid or sodium hydroxide, shake well, and you're done.
  • Test method Take a certain amount of the test sample (crystal form prepared in Example 1), add the medium with the corresponding pH one by one, and continue to shake until it reaches the saturation state, record the weight of the test sample and the amount of solvent, Calculate the concentration when dissolving the sample, and the test results show that the crystal form of the compound of formula A has good solubility in different pH.
  • the test method is:
  • Dryer humidity 80% ⁇ 2%RH.
  • Test process Take an appropriate amount of the crystal form prepared in Example 1 and place it on a clean watch glass, open it, and place it under the conditions of light 4500lx ⁇ 500lx, high temperature 60°C, high humidity 92.5%RH for 5 days and 10 days, respectively. Traits, related substances, and compare with the 0-day result to check the stability.
  • test product solution Take about 10 mg of each test product, place in a 10 ml measuring bottle, add 50% acetonitrile to dissolve and dilute to the mark, shake well, and filter as the test product solution. Accurately measure 10 ⁇ l of the sample solution, inject the sample according to the above chromatographic method, and calculate the maximum single impurity and total impurity according to the area normalization method.
  • the test results show that the crystal form of the compound of formula A has good stability under high temperature and high humidity. The largest single impurity does not exceed 0.1%, while the total impurity does not exceed 0.4%. And the inventor found that the stability of the crystal form of the compound of formula A under light conditions is worse than the stability under high temperature and high humidity, but still has relatively good stability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline du composé hétérocyclique représenté par la formule A ou un hydrate de celui-ci, son procédé de préparation et son utilisation. La forme cristalline du composé de formule A ou d'un hydrate de celui-ci présente une solubilité, une hygroscopicité et une stabilité supérieures par rapport à sa forme amorphe. En outre, la forme cristalline présente également une meilleure biodisponibilité que la forme amorphe. De plus, son procédé de préparation est simple, et par conséquent il présente un aspect pratique plus élevé.
PCT/CN2020/071479 2019-01-10 2020-01-10 Forme cristalline d'un composé hétérocyclique servant d'antagoniste du récepteur crth2 WO2020143781A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080007335.XA CN113382995A (zh) 2019-01-10 2020-01-10 作为crth2受体拮抗剂的杂环化合物的晶型

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910024247.X 2019-01-10
CN201910024247 2019-01-10

Publications (1)

Publication Number Publication Date
WO2020143781A1 true WO2020143781A1 (fr) 2020-07-16

Family

ID=71521977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/071479 WO2020143781A1 (fr) 2019-01-10 2020-01-10 Forme cristalline d'un composé hétérocyclique servant d'antagoniste du récepteur crth2

Country Status (2)

Country Link
CN (1) CN113382995A (fr)
WO (1) WO2020143781A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896178A (zh) * 2007-10-10 2010-11-24 凯米科技公司 作为crth2受体拮抗剂的杂环化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696222B2 (en) * 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896178A (zh) * 2007-10-10 2010-11-24 凯米科技公司 作为crth2受体拮抗剂的杂环化合物

Also Published As

Publication number Publication date
CN113382995A (zh) 2021-09-10

Similar Documents

Publication Publication Date Title
CN110088105B (zh) Jak家族激酶的小分子抑制剂
JP6633531B2 (ja) 炎症性障害の治療のための医薬組成物
EP2197438B1 (fr) Composés hétérocycliques comme antagonistes du récepteur crth2
EP2346865B1 (fr) Dérivés d'indole comme antagonistes du récepteur crth2
AU2006281937B2 (en) Indole derivatives as CRTH2 receptor antagonists
JP5717727B2 (ja) ２−（４−（（２−アミノ−４−メチル−６−（ペンチルアミノ）ピリミジン−５−イル）メチル）フェニル）酢酸４−（ジメチルアミノ）ブチルの二サッカリン塩、二フマル酸塩、二ｌ−ヒドロキシ−２−ナフトエ酸塩および一安息香酸塩
US8507005B2 (en) Particulates of a CRTH2 antagonist
CN104603123B (zh) 曲格列汀的固态形式及其制备方法和用途
CN102164894A (zh) 前列腺素d2受体的杂芳基拮抗剂
SK932003A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
TWI699206B (zh) Ｎ-(５-氰基-４-((２-甲氧乙基)胺基)吡啶-２-基)-７-甲醯基-６-((４-甲基-２-側氧基哌-１-基)甲基)-３,４-二氫-１,８-萘啶-１(２ｈ)-甲醯胺之顆粒
CN103228654A (zh) 作为JAK抑制剂的咪唑并[1,2-b]哒嗪以及咪唑并[4,5-b]吡啶衍生物
CN103974953A (zh) 激酶抑制剂
JP2021046404A (ja) Ｏｌｉｇ２活性の阻害
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
TW202016110A (zh) Ｊａｋ激酶家族之小分子抑制劑
TW200526657A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
TW201706259A (zh) 結晶形式
WO2020143781A1 (fr) Forme cristalline d'un composé hétérocyclique servant d'antagoniste du récepteur crth2
CN108290898A (zh) 作为磷脂酰肌醇3-激酶抑制剂的喹啉类似物
US20070027171A1 (en) Cycloalkanepyrrolopyridines as dp receptor antagonists
CN104341343B (zh) 贝曲西班的晶型及其制备方法和用途
JP2511204B2 (ja) 置換インド―ル
US20220048918A1 (en) Pkc inhibitor solid state forms
TWI752553B (zh) 嘧啶衍生物的優勢鹽型及其晶型

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20739131

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20739131

Country of ref document: EP

Kind code of ref document: A1